University of Patras
Προσδιορισμός της διαφορικής μοριακής υπογραφής τριών αιμοποιητικών ιστών κατά την ανθρώπινη οντογένεση και εφαρμογή της στη θεραπευτική των αιμοσφαιρινοπαθειών β-τύπου
Abstract
dc:descriptionHemoglobinopathies are a heterogeneous group of hereditary disorders resulting from mutations in the globin genes. Clinically, the most important hemoglobinopathies are sickle cell anemia and β-thalassemia that are caused by qualitative and quantitative disorders, respectively. The clinical phenotype of patients with β-type hemoglobinopathies varies due to the wide variety of mutations found in the β-globin gene and in genes outside the β-globin locus that are involved in the erythroid and non- erythroid mechanism of regulation of this particular gene expression.Hydroxyurea (HU) is the only pharmaceutical agent approved by the Food and Drug Administration of the United States of America that contributes to the induction of HbF composition and is used to treat sickle cell anemia and β-thalassemia. In the context of precision medicine and considering interindividual variability in HU response, the tailored-made administration of HU is considered necessary towards maximum patient benefit. For this, we need to delineate the mechanisms of interindividual variabilityAccording to current literature data and outcome of our research strategy in the laboratory, single nucleotide polymorphisms within and outside the β-globin complex have been found to be associated both with elevated HbF levels in β-thalassemia patients with mild clinical phenotype and the response of patients with β-type hemoglobinopathies to HU administration.In the present thesis based on the different sites of erythropoiesis in human ontogenesis and the time of switch from γ- to β-globin, the differential transcriptional profile of progenitor erythroid cells from fetal liver, umbilical cord blood and adult peripheral blood were studied by DNA microarray methods. From the list of the differentially expressed genes and after extensive literature search and pathway analysis, we chose to further study the VEGFA gene. This gene was found to be overexpressed in later stages of ontogenesis where low levels of HbF are found.The differential expression of the VEGFA gene was then thoroughly investigated during the differentiation of early erythroid cells from two tissues with high levels of HbF (human fetal liver and umbilical cord blood) in erythroblasts. More specifically, the molecular imprint of BFU-Es, CFU-Es and erythroblasts was analyzed with the RNA sequencing method. The VEGFA gene was found to be overexpressed in the earliest forms of erythroid cells relatively to the more mature forms in these tissues.Subsequently, we explore the role of the VEGFA gene as a modifier of β-thalassemia disease severity and as a pharmacogenomic marker for the response of patients with β-hemoglobinopathies to HU treatment. For this, following in silico analysis, we chose to study the SNPs rs2146323, rs3024997 and rs10434 across VEGFA in Caucasians. In particular, genotyping analysis of the above polymorphisms in five population groups was performed: healthy subjects, non-transfusion dependent β-thalassemia patients, major β-thalassemia patients, and compound heterozygous patients for sickle cell disease and β-thalassemia characterized as responders and non-responders in HU. rs2146323 and rs10434 were analyzed by Sanger sequencing and the Allele-Specific PCR method was employed for rs3024997.rs2146323 was found to be associated with elevated HbF levels and thus the mild phenotype of patients with intermediate β-thalassemia. In contrast, rs3024997 seems to be associated with the most severe clinical phenotype of major β-thalassemia patients. Regarding the correlation of variants in question with response to HU of sickle cell disease/ β-thalassemia patients, rs2146323 was found to be significantly associated.Based on the findings of our study, the VEGFA gene is overexpressed in low HbF context. Also, genotyping analysis’ results hold promise about its use in the individualized treatment of patients with β-hemoglobinopathies.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Chondrou, Vasiliki
- Χονδρού, Βασιλική
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42613